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SUMMARY  Pimecrolimus (SDZ ASM 981), an ascomycin deriva-
tive, as one of the new classes of immunomodulating macrolac-
tams, is specifically effective in the treatment of inflammatory skin 
diseases. The interest in pimecrolimus is highly important for its 
significant anti-inflammatory activity, cell-selective inhibition of 
inflammatory cytokines, immunomodulatory capabilities, and low 
systemic immunosuppressive potential. The mechanism of action 
of pimecrolimus is the blockage of T cell activation, blocking signal 
transduction pathways in T cells, and inhibition of the synthesis of 
inflammatory cytokines, specifically Th1- and Th2-type cytokines. 
Several studies have evaluated the effectiveness of pimecrolimus 
as the treatment of choice for inflammatory skin diseases.
KEY WORDS: Elidel; ascomycin; pimecrolimus; immunosup-
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 INTRODUCTION
 Topical immunological modulators (TIMs) 
(tacrolimus and pimecrolimus) are new exciting 
agents in the treatment of inflammatory skin dis-
eases, particularly for the treatment of atopic der-
matitis (AD) (1-14). Since the first use of tacrolimus 
in patients in the mid 1990s, and of pimecrolimus 
thereafter, extensive clinical experience has shown 
them to be an effective, well tolerated alternative to 
topical steroids in the treatment of AD. Both TIMs 
showed good safety profile with longterm use in 
clinical setting. Pimecrolimus (SDZ ASM 981), an 
ascomycin derivative, is one of the new classes 
of immunomodulating macrolactams and is spe-
cifically effective in the treatment of inflammatory 
skin diseases. Pimecrolimus 1% cream (Elidel) 
is currently the most advanced ascomycin mac-
rolactam under development. The mechanism of 
action of pimecrolimus is the blockage of T cell ac-
tivation. Like all ascomycins, pimecrolimus is an 
immunophilin ligand, which binds specifically to 
the cytosolic receptor, immunophilin macrophilin-
12. This pimecrolimus-macrophilin complex effec-
tively inhibits the serin phosphatase calcineurin, 
by preventing calcineurin from dephosphorylating 
the nuclear factor of activated T cells (NF-AT), a 
transcription factor. The results with pimecrolimus 
showes the blockage of signal transduction path-
ways in T cells and the inhibition of the synthesis 
of inflammatory cytokines, specifically Th1- and 
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Th2-type cytokines. Pimecrolimus has also been 
shown to prevent the release of cytokines and 
proinflammatory mediators from mast cells. Sev-
eral studies have evaluated the effectiveness of 
pimecrolimus as a treatment for inflammatory skin 
diseases such as AD, allergic contact dermatitis 
(ACD), autoimmune diseases, psoriasis, sebor-
rheic dermatitis, etc. (1,2,8,14,15).
 Pimecrolimus 1% cream is approved in the 
United States for the treatment of AD. Pimecrolim-
us is a calcineurin inhibitor that functions as a topi-
cal immunosuppressant (1,2). Topical pimecrolim-
us has proved safe and effective in children with 
moderate AD. It has also proved effective in other 
inflammatory skin diseases.
 PIMECROLIMUS IN PSORIASIS
 In the treatment of psoriasis, topical use of 
pimecrolimus has proved promising (3). As oral 
agents, both tacrolimus (4) and pimecrolimus (5) 
were shown in pilot studies to be effective in the 
treatment of moderate to severe plaque psoriasis. 
Some have stated that given orally, pimecrolimus 
is as potent or superior to tacrolimus in treating 
ACD in mice and rats (6). However, no trial com-
paring these medications systemically in humans 
has yet been performed. 
 Neither tacrolimus ointment (7) nor pimecrolim-
us (3,8) cream appear effective in treating plaque-
type psoriasis when simply applied in the commer-
cially available form. In a dose-binding pilot study 
by comparing five dose of oral pimecrolimus in the 
treatment of moderate to severe plaque psoriasis 
(5 mg o.d., 10 mg o.d., 20 mg o.d., 20 mg b.i.d. 
and 30 mg b.i.d.) were compared with placebo, 
the agent effectiveness was proven in 38 patients 
(8). However, neither medication has yet been ap-
proved by the US Food and Drug Administration 
(FDA) for this indication. In case of tacrolimus, this 
is so although higher percutaneous drug absorp-
tion has been demonstrated in diseased skin than 
in healthy skin (9). In a pilot study of 70 patients, 
23 of them in the calcipotriol (0.05%) twice-daily 
group, 24 in the tacrolimus (0.3%) ointment once-
daily group, and 23 in the placebo group, tacroli-
mus was not effective in the treatment of psoriasis 
(10-13). 
 Occlusion is also associated with increased ef-
fectiveness of pimecrolimus in treating psoriasis 
(14,15). Pimecrolimus (0.3% and 1.0% cream) 
under occlusion was used to treat ten patients 
with chronic plaque-type psoriasis (16). For con-
trol treatment, the corresponding ointment base 
(placebo) and open-labeled clobetasol-17-propio-
nate ointment (0.05%) were used. The trial was 
designed as a randomized, double-blind, within-
subject comparison over 2 weeks using the micro-
plaque assay. Evaluation was performed by daily 
determination of clinical scores for erythema and 
induration. The results of the study showed that 
after 2 weeks of treatment, total scores decreased 
by 92 percent for clobetasol, by 82 percent for 
pimecrolimus (0.1%), by 63 percent for pimecro-
limus (0.3%), and by 18 percent for the ointment 
base (placebo) (3).
 A significant therapeutic effect of pimecrolimus 
in treating psoriasis without occlusion, where 
pimecrolimus had greater efficacy than the ve-
hicle, although being less efficacious than calci-
potriol and clobetasol ointment, has been reported 
by Gupta and Chow in their review including the 
study of Mrowietz et al. (8). Changing the formula-
tion of pimecrolimus to increase its penetration is 
also a promising means to increase its efficacy in 
treating psoriasis (3).
 While the role of pimecrolimus in the treatment 
of psoriasis remains to be defined, its use is likely 
to increase. Additional investigations are needed 
to determine ideal formulations of pimecrolimus for 
particular body sites in the treatment of psoriasis. 
 Pimecrolimus (Elidel, SDZ ASM 981), a new 
macrolactam ascomycin derivative, was highly ef-
fective in treating plaque-type psoriasis when ap-
plied under Finn-chamber occlusion. A two-center, 
randomized, double-blind, vehicle- and positive-
control patient study was therefore conducted in 
23 adult psoriasis patients. Pimecrolimus 1% in 
an experimental ointment formulation was applied 
twice daily, along with a corresponding vehicle, 
0.005% calcium ointment, and 0.05% clobeta-
sol-17-propionate ointment to test the sites with-
out occlusion, for 21 days. Erythema, induration 
and scaling (score: 0 [absent] to 4 [severe]) were 
evaluated. The total sign score was defined as 
the sum of the erythema, induration and scaling 
scores (range 0-12). Pimecrolimus 1% ointment 
was significantly (p=0.03) more effective than the 
corresponding vehicle, with an improvement in 
total sign score of 51.4% compared with 36.7% 
for the corresponding vehicle. Improvements 
with calcipotriol and clobetasol-17-propionate 
were 71.5% and 88.3%, respectively. No local or 
systemic drug side effects were observed in the 
study. The authors concluded that pimecrolimus 
1% cream experimental ointment formulation was 
significantly more effective than the correspond-
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ing vehicle but less effective than calcipotriol and 
clobetasol cream (3,8). The first study reporting a 
significant therapeutic effect of pimecrolimus in an 
ointment formulation applied without occlusion to 
psoriatic plaques was that performed by Mrowietz 
et al. (17). Topical calcineurin inhibitor (pimecroli-
mus 1% cream) provided control of inflammation 
without causing longterm adverse effects such as 
skin atrophy and striae. Pimecrolimus 1% cream 
is a safe and effective treatment for intertriginous 
psoriasis (18).
 PIMECROLIMUS IN ATOPIC DERMATITIS
 There have been several human studies 
evaluating the efficacy of pimecrolimus in AD. 
Pimecrolimus is effective and safe in both chil-
dren and adults with AD. When pimecrolimus 1% 
cream was applied for adult AD, improvement was 
observed as early as the first week, with a 72% 
reduction in severity after 3 weeks. Transient ir-
ritation may occasionally be experienced at the 
site of pimecrolimus cream application. Similar 
results have also been described in children aged 
3 months and older following the application of 
pimecrolimus 1% cream (8). Pimecrolimus has an 
enormous potential as a new treatment of inflam-
matory skin diseases; it has proved effective in 
atopic and allergic contact dermatitis, with no un-
favorable adverse effect profile, including little ef-
fect on the systemic immune response (8). Luger 
et al. (19) assessed the use of topical pimecroli-
mus in AD patients who had 5% to 30% total body 
surface area involvement (n=260). Subjects were 
randomly assigned to treatment with pimecrolimus 
cream 0.05%, 0.2%, 0.6% or 1.0% vehicle cream, 
or with 0.1% betamethasone-17-valerate cream 
applied twice daily for 3 weeks. Pimecrolimus 1% 
and 0.6% cream were both effective, whereas 
pimecrolimus 0.05% had no significant effect (19). 
In their review including the study of Harper et al., 
Gupta and Chow (8) conclude that pimecrolimus 
was well tolerated and effective in pediatric pa-
tients, even as young as 3 months, regardless of 
the extent of body surface involvement or duration 
of treatment. 
 Topical applications are indicated for treating 
AD. In this indication, it represents an alternative 
or an adjuvant to topical corticosteroids. Pimecro-
limus may also prove beneficial in the treatment 
of other dermatoses (20). When applied at the 
first signs or symptoms of AD, Elidel prevents 
flare progression and improves longterm disease 
control. Pimecrolimus cream 1% (Elidel) applied 
twice daily showed greatest efficacy and was se-
lected for subsequent studies in adults, children 
and infants with AD. Elidel is a steroid-free cream 
containing 1% strength of the topical immunomod-
ulator pimecrolimus. Elidel was specifically devel-
oped as a treatment for AD and is approved for 
use in children as young as 2 years of age. The 
production of inflammatory cytokines by activated 
T cells in skin is thought to play an important role 
in the pathogenesis of AD. Elidel potently sup-
presses cytokine production by dermal T cells 
without significantly impairing systemic immune 
responses. Elidel does not cause steroid-associ-
ated local effects such as dermal atrophy, striae, 
or telangiectasias. In randomized controlled clini-
cal studies, twice-daily application of Elidel was 
shown to significantly improve the signs and symp-
toms of AD in infants, children and adults (21). 
The clinical effect of Elidel on pruritus, the most 
troublesome symptom of AD, can be observed 
within 1 week of therapy and is maintained for the 
duration of treatment. Elidel is well tolerated; the 
risk of application-site reactions such as itching 
or burning is comparable with that of the vehicle. 
Adverse effects were generally mild in patients re-
ceiving Elidel and occurred at rates comparable 
with those in patients receiving vehicle treatment. 
In a 1-year study, Elidel significantly reduced the 
incidence of flares when used at the first signs and 
symptoms of acute AD. As the result, the overall 
corticosteroid use to treat flares was significantly 
lower in patients using Elidel for early interven-
tion (21).
 Meurer et al. (22) compared the safety and ef-
ficacy of pimecrolimus cream 1%-based treatment 
versus conventional therapy in adults with mod-
erate AD. Patients were randomized to receive 
pimecrolimus cream 1% (n=62) or vehicle (n=68) 
at the first signs/symptoms of AD, for 24 weeks 
as required. A moderately potent topical cortico-
steroid (prednicarbate 0.25% cream) was allowed 
in both groups to treat flares. Corticosteroids were 
required on fewer days in the pimecrolimus group 
compared with the vehicle group (9.7 vs. 37.8%, 
p<0.001). Furthermore, 59.7% of pimecrolimus-
treated patients experienced no flares during the 
study period compared with 22.1% of vehicle-
treated patients (p<0.001). Pimecrolimus cream 
1% was well tolerated throughout the study. For 
adults with moderate AD, pimecrolimus cream 1% 
is well tolerated, reduces the incidence of flares, 
reduces/eliminates corticosteroid use, improves 
longterm disease control, and enhances the pa-
tients’ quality of life (22). Systemic absorption is 
very low and no accumulation is observed (8).
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 Luger et al. (23) performed a randomized, dou-
ble-blind, multicenter study comparing the long-
term safety and tolerability of pimecrolimus cream 
1% and topical corticosteroids (TCS) in 658 adults 
with moderate to severe AD. Patients applied ei-
ther pimecrolimus or TCS (i.e. 0.1% triamcinolone 
acetonide cream and/or 1% hydrocortisone ac-
etate cream) twice daily to all affected areas until 
complete clearance or for up to 1 year. A major-
ity of patients treated with either pimecrolimus or 
TCS used the drug on a continuous basis over 1 
year. In patients who had >30% of body surface 
involved by AD, the incidence of all skin infections 
was significantly lower in the pimecrolimus group 
than in the TCS group (95% CI of treatment dif-
ference, -25.3% to -3.4%). The most frequent ap-
plication site reaction was burning (25.9% of pa-
tients on pimecrolimus and 10.9% on TCS), which 
was transient and mild to moderate in most cases. 
Three TCS-treated patients reported skin striae. 
There were no treatment-related serious or clini-
cally significant systemic adverse events. The ef-
ficacy was better in patients on continuous TCS 
therapy, although patients completing the study 
were similarly well-controlled in both groups. About 
42% of the pimecrolimus-treated patients were 
maintained for 1 year without TCS. Pimecrolimus 
demonstrated a favorable safety profile when used 
to treat adult patients with moderate to severe AD 
for up to 1 year. A significant proportion of patients 
could be maintained without TCS for a year (23).
 Allen et al. (24) measured pimecrolimus blood 
concentrations and evaluated tolerability and ef-
ficacy in children and infants treated topically for 
AD with pimecrolimus cream 1% for three weeks. 
Three open-label, noncontrolled, multiple topical 
dose studies were conducted in children aged 
8-14 years (study A, ten patients), and in infants 
aged 8-30 months (study B, eight patients) and 4-
11 months (study C, eight patients). Pimecrolimus 
blood concentrations were determined on days 4 
and 22 of treatment, and at end of study. Efficacy 
was assessed using the Eczema Area and Sever-
ity Index (EASI). Pimecrolimus blood concentra-
tions were consistently low, typically (81%) below 
1 ng/ml, with more than half of the measurements 
below the assay limit of quantitation (0.5 ng/ml) 
in studies A and B. The highest blood concentra-
tion measured throughout the three studies was 
2.6 ng/ml. The cream was well tolerated, locally 
and systemically. The most common adverse 
event suspected to be related to study medica-
tion was a transient mild to moderate stinging 
sensation at the application site in 5/26 patients. 
There was no indication of any systemic adverse 
effect. The patients responded well to therapy with 
a rapid onset of action, usually within four days. 
Median reductions of EASI from baseline at day 
22 were 55% (study A), 63% (study B), and 83% 
(study C). Three-week treatment with pimecroli-
mus cream 1% twice daily in children and infants 
with extensive AD is well tolerated and results in 
minimal systemic exposure. Therapy with Elidel/
pimecrolimus cream applied twice daily proved 
safe and effective for significantly reducing the 
severity of symptoms in 251 children (aged 3-23 
months) with mild to moderate AD in studies of 
up to one-year duration (25,26). Early interven-
tion with pimecrolimus to prevent progression to 
disease flare proved significantly more effective 
than conventional management of AD (25). Ear-
ly treatment of AD may alter the so called atopic 
march, as studies have suggested that AD might 
be a risk factor for the development of allergic dis-
eases of the respiratory tract. The efficacy of topi-
cal corticosteroids directly correlates with safety 
concerns: as potency increases, so does the po-
tential for side effects. There is a significant need 
for pimecrolimus in AD therapies, particularly for 
the treatment of moderate to severe disease. Op-
timal AD therapy should be at least as effective as 
conventional treatment, have an excellent safety 
profile, and offer the potential to prevent flares 
and modify the disease (25). Pimecrolimus mono-
therapy provides a real alternative for treatment 
challenges associated with conventional AD ther-
apy. Analysis of flare-prevention rates observed in 
several clinical trials indicates that more children 
remain flare-free with pimecrolimus compared 
with other TIMs (25,26). Pimecrolimus combines 
high anti-inflammatory activity in the skin with a 
low potential to impair systemic immune reactions. 
Multicenter studies demonstrated the efficacy and 
safety of pimecrolimus cream in patients with AD 
and confirmed it to be suitable for short-term treat-
ment and longterm management of AD in adults, 
children and infants as young as 3 months. Topi-
cal application in humans is not associated with 
atrophogenic side effects observed with cortico-
steroids. Pimecrolimus blood levels remained 
consistently low after repeated topical application 
and no clinically relevant drug-related systemic 
adverse events have been reported among 8000 
patients treated in clinical trials so far. Short-term, 
phase I/II and phase II trials of pimecrolimus ad-
ministered orally in psoriasis and AD have shown 
that this drug is highly effective in a dose-de-
pendent manner in patients with these diseases, 
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and has a favorable safety profile. This finding is 
confirmed by pharmacogenomic blood analysis. 
Available data indicate that pimecrolimus, in both 
cream and oral formulations, may represent a new 
option for the treatment of inflammatory skin dis-
eases (27). Pimecrolimus cream 1% is an effica-
cious and well-tolerated treatment for infants and 
children with mild and moderate AD, which makes 
it a promising new therapy for the clinical care in 
pediatric AD patients (28-31).
 PIMECROLIMUS IN CHRONIC HAND 
 ECZEMA
 A multicenter, randomized, vehicle-controlled, 
3-week study was conducted in patients with 
chronic hand dermatitis (HD) of various etiologies 
and locations to identify subgroups particularly 
responsive to twice-daily application of pimecro-
limus cream 1% with overnight occlusion (32). A 
total of 294 patients were randomized to the study. 
By the final visit on day 22, there was a trend to-
wards greater clearance in patients who received 
pimecrolimus than in those treated with vehicle 
cream. The analysis of treatment success by vari-
ous stratification factors revealed that palmar in-
volvement had notable impact on the response 
(p=0.33). Patients in the pimecrolimus group con-
tinued to improve throughout the study; however, 
in the vehicle group, improvement plateaued after 
15 days. Pimecrolimus was well tolerated, with a 
low rate of application-site reactions such as burn-
ing. Pimecrolimus cream 1%, when used twice 
daily with overnight occlusion, may be of benefit in 
the management of chronic HD (32).
 PIMECROLIMUS IN ALLERGIC CONTACT   
 DERMATITIS
 In human studies of ACD, pimecrolimus 1% 
cream proved to be significantly more effective 
than control treatment. Also, efficacy of pimecro-
limus 0.6% was comparable to that of 0.1% be-
tamethasone-17-valerate, however, pimecrolimus 
was not associated with any of the side effects 
characteristic of topical steroids. Topical applica-
tion of pimecrolimus is not associated with skin 
atrophy (8). 
 Contact dermatitis is a common clinical prob-
lem, with prevalent sensitizers being cosmetics, 
metals, medicines, and plants. Plants of the genus 
Toxicodendron cause ACD in 50% to 70% of the 
population (33). There are studies supporting the 
effectiveness of macrolactams when administered 
before antigen challenge, but there are no stud-
ies describing the effectiveness of these drugs in 
the treatment of established human ACD. To in-
vestigate the effect of topical pimecrolimus in the 
treatment of Toxicodendron-induced ACD once 
rash is evident, poison ivy tincture was applied bi-
laterally to anterior forearms of 12 subjects with 
Finn chambers (Allerderm Diagnostic Products, 
Petaluma, CA) (33). After dermatitis had become 
evident, the volunteers treated each arm twice 
daily with either 1% topical pimecrolimus cream or 
placebo in a blinded fashion. The outcomes mea-
sured were a dermatitis grading score and time 
to rash and itch resolution. The median ± SEM 
time for rash resolution was 16.55±1.59 days in 
the treatment group and 16.27±1.82 days in the 
placebo group (p=0.601). The median time for itch 
resolution was 4.73±1.56 days in the treatment 
group and 4.91±1.59 days in the placebo group 
(p=0.167). The mean dermatitis score was 2.26± 
0.17 in the treatment group and 2.32±0.15 in the 
placebo group (p=0.62). The application of topi-
cal pimecrolimus was ineffective in the treatment 
of ongoing Toxicodendron-induced ACD (33). The 
study by Quelle-Rousset et al., reviewed by Gupta 
and Chow (8) was the first controlled trial where 
pimecrolimus (0.2% and 0.6% cream) demonstrat-
ed efficacy in 66 nickel ACD during 12-day twice 
daily treatment with both concentrations. The wide 
array of inflammatory skin diseases treated suc-
cessfully with pimecrolimus cream 1% has been 
demonstrated by Professor Luger, i.e. psoriasis, 
Netherton’s syndrome, hand eczema, perioral 
eczema, dyshidrotic eczema, seborrheic dermati-
tis, perioral dermatitis, chronic actinic dermatitis, 
steroid induced rosacea, vitiligo, pyoderma gan-
grenosum, granuloma annulare, lichen sclerosus 
et atrophicus, oral and genital lesions in Crohn’s 
disease, and discoid lupus erythematosus (34).
 CONCLUSION
 Pimecrolimus 1% cream has a promissing im-
munomodulatory potential as topical treatment for 
inflammatory skin disease and is ideal treatment 
option for AD. Pimecrolimus provides safe and ef-
fective longterm management for moderate to se-
vere AD, and to prevent the disease progression, 
then for ACD and other inflammatory skin diseas-
es as well as psoriasis. It reduces or eliminates 
the need of topical corticosteroids. Pimecrolimus 
1% cream provides an excellent treatment alter-
native to topical corticosteroids and steroid-spar-
ing therapies. Elidel is an agent for pre-emptive 
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patient self-management, for use in all age groups 
and safely applied to all skin surface and even on 
sensitive  areas including face, neck, intertriginous 
lesions and skin folds.
 At last, pimecrolimus improves the quality of 
life of patients with AD, and of their families.
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